Therapeutic use of anti-CS1 antibodies
View Patent ↗The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
1. A monoclonal antibody or antigen binding fragment that binds a protein encoded by SEQ ID NO:1 and inhibits immunoglobulin secretion, wherein said antibody or antigen binding fragment decreases by at least 50% in a competitive binding assay the binding to the protein encoded by SEQ ID NO:1 of a control antibody, wherein the control antibody comprises a VH region comprising SEQ ID NO:7 and a VL region comprising SEQ ID NO:8.
2. The monoclonal antibody or antigen binding fragment of claim 1 which inhibits immunoglobulin secretion by at least 40%.
3. The monoclonal antibody or antigen binding fragment of claim 1 which is an IgG 1 .
4. The monoclonal antibody of claim 1 which is a human or humanized antibody.
5. A conjugate compound comprising a monoclonal antibody or antigen binding fragment according to claim 1 linked to an effector moiety or a detectable label.
6. The conjugate compound of claim 5 in which the antibody or antigen binding fragment is linked to a detectable label.
7. The conjugate compound of claim 5 in which the detectable label is a radioactive compound, a fluorescent compound, an enzyme, a substrate, an epitope tag or a toxin.
8. The conjugate compound of claim 5 in which the antibody or antigen binding fragment is linked to an effector moiety.
9. The conjugate compound of claim 8 in which the effector moiety is a cytotoxic agent.
10. The conjugate compound of claim 8 in which the effector moiety is a detection moiety, an activatable moiety, a chemotherapeutic agent, a lipase, an antibiotic, a chemoattracting moiety, an immune modulator, or a radioisotope.
11. A pharmaceutical composition comprising the antibody or antigen binding fragment of claim 1 .
12. A pharmaceutical composition comprising the conjugate compound of claim 5 .
13. A method of treating a plasma cell neoplasm, comprising administering to a patient in need thereof the antibody or antigen binding fragment of claim 1 .
14. The method of claim 13 , wherein the plasma cell neoplasm is multiple myeloma.
15. A method of treating a plasma cell neoplasm, comprising administering to a patient in need thereof the conjugate compound of claim 5 .
16. The method of claim 15 , wherein the plasma cell neoplasm is multiple myeloma.